Ampersand Biomedicines
John McGrath is a Principal Scientist with experience in developing novel droplet microfluidic instrumentation for biologics discovery and therapeutic cell line development. Previously held roles as a Senior Researcher and Scientific Project Manager managing the scientific network of EVOdrops at the University of Glasgow. Postdoctoral Fellow at the University of Virginia specializing in microfluidic devices for cell detection and sorting. Holds a PhD in Physics and a Bachelor of Science in Cell & Molecular Biology.
This person is not in any offices
Ampersand Biomedicines
Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.